Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2003) 5 P190

BES2003 Poster Presentations Neuroendocrinology and Behaviour (16 abstracts)

Single centre audit of surgical outcome in acromegaly

SE Baldeweg 1 , GS Conway 2 , M Powell 3 & M Vanderpump 1


1Department of Endocrinology, Royal Free Hospital, London, UK; 2Department of Endocrinology, The Middlesex Hospital, London, UK; 3Department of Neurosurgery, The National Hospital for Neurology and Neurosurgery, London, UK.


The results of transsphenoidal surgery for acromegaly by a single neurosurgeon (MP) operated between 1981 and July 2002 were examined retrospectively. 141 database and case note records for patients with a clear pre-operative diagnosis of acromegaly were reviewed. Patients with incomplete pre- or postoperative data on growth hormone (GH) status were excluded from further analysis (n=14). The remaining 127 formed the audit group.
Pituitary imaging data was available in 84 of those patients showing microadenomas in 17 (20%) patients and macroadenomas in 68 (80%) patients.
Cure was assessed according to biochemical criteria.
Nadir GH during GTT or random GH <1.5 mU per litre: cure rate was 60 (47%), 11 (65%) and 21 (31%) for overall cure, microadenomas and macroadenomas respectively.
Nadir GH during GTT or random GH <2.5 mU per litre: cure rate was 78 (61%), 12 (71%) and 37 (54%) for overall cure, microadenomas and macroadenomas respectively.
Nadir GH during GTT or random GH <5 mU per litre: cure rate was 96 (76%), 15 (88%) and 47 (69%) for overall cure, microadenomas and macroadenomas respectively.
Surgical cure rate depended on cure criteria and tumor size. Random preoperative GH and cure rate were not significantly correlated.
Our data compares with previous surgical series (surgical remission rates from 21-46%). These findings confirm transsphenoidal surgery to be an effective primary therapy for acromegaly. Cure rate is higher in patients with microadenomas. By most stringent cure criteria, less than half of patients will require adjuvant therapy to achieve a cure.

Volume 5

22nd Joint Meeting of the British Endocrine Societies

British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts